JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Затворен

СекторЗдравеопазване

16.76 0.96

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.4

Максимум

16.95

Ключови измерители

By Trading Economics

Продажби

132M

160M

Служители

627

EBITDA

126M

4M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+79.11% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

882M

1.9B

Предишно отваряне

15.8

Предишно затваряне

16.76

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Arcus Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2025 г., 20:49 ч. UTC

Печалби

Correction to Thermo Fisher Article on Oct. 22

23.10.2025 г., 23:51 ч. UTC

Пазарно говорене

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23.10.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23.10.2025 г., 22:58 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

23.10.2025 г., 22:57 ч. UTC

Пазарно говорене

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -2-

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23.10.2025 г., 22:17 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23.10.2025 г., 21:41 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23.10.2025 г., 21:05 ч. UTC

Печалби

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.10.2025 г., 20:35 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23.10.2025 г., 20:28 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23.10.2025 г., 20:15 ч. UTC

Пазарно говорене
Печалби

Global Commodities Roundup: Market Talk

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Adj EPS $1.71

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Sales $5.52B

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q EPS $1.67

23.10.2025 г., 20:09 ч. UTC

Печалби

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23.10.2025 г., 20:07 ч. UTC

Печалби

Blackstone Looks to IPOs for Investment Exits -- Update

23.10.2025 г., 20:05 ч. UTC

Печалби

Intel 3Q Gross Margin 38.2% >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel: 4Q Guidance Excludes Altera >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Sees 4Q Adj EPS 8c >INTC

Сравнение с други в отрасъла

Ценова промяна

Arcus Biosciences Inc Прогноза

Ценова цел

By TipRanks

79.11% нагоре

12-месечна прогноза

Среден 32.33 USD  79.11%

Висок 54 USD

Нисък 14 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcus Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

8.01 / 8.75Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat